Geistlich Sons

What Geistlich Sons does

Geistlich Pharma AG is a Swiss family-owned medical device and biomaterials company founded in 1851, headquartered in Wolhusen, Switzerland. Originally Switzerland's first glue factory processing animal bones and hides, the company pivoted into regenerative medicine in the 1980s when third-generation chemist Dr. Peter Geistlich collaborated with researchers to develop Geistlich Bio-Oss, a natural bone substitute now considered the global gold standard in regenerative dentistry. The company's core technology centers on processing bovine bone and porcine collagen into regenerative biomaterials, including bone substitutes (Bio-Oss, Orthoss), collagen membranes (Bio-Gide, Chondro-Gide), and 3D collagen matrices (Mucograft, Fibro-Gide, Derma-Gide). Geistlich's proprietary 5-week (890-hour) manufacturing process for Bio-Oss preserves the natural bone microstructure, and its Chondro-Gide bilayer collagen I/III membrane underpins the proprietary AMIC cartilage repair technique.

The company sells primarily to healthcare professionals — dental surgeons, periodontists, implantologists, orthopedic surgeons, sports medicine specialists, and wound care clinicians — across over 110 regions globally, reaching customers through 12 wholly-owned subsidiaries (UK, Germany, Italy, France, China, Brazil, South Korea, North America, Australia, New Zealand, India, Japan), direct field sales, e-commerce shops in major markets, and a global distributor network. Geistlich generates revenue primarily through one-time product sales of medical devices and biomaterials, with over 2800 peer-reviewed scientific publications supporting its products and a Geistlich product being used clinically every 14 seconds worldwide. The portfolio extends across dental, orthopedic, wound care, and infectiology applications, and is reinforced by three proprietary foundations (Osteology Foundation founded 2003, Osteo Science Foundation founded 2013, ON Foundation founded 2018) that channel research funding and connect Geistlich to global clinical leaders.

Geistlich operates with 800+ employees globally as of 2026 (its 175th anniversary year), is ISO/IEC 27001:2022 certified, and remains family-controlled under Chairman Dr. Andreas Geistlich. Recent strategic activity includes a 2019 Wolhusen facility expansion, ongoing geographic buildout through new subsidiaries (India, Brazil), and a February 2026 FDA 510(k) clearance for DermaForm obtained through a partnership with StimLabs, marking formal entry into the US advanced wound care market.

Name

Geistlich Sons

Legal name

Geistlich Sons Limited

Website

https://geistlich.com

Company type

Private

Founded year

1851

Operating status

Operating

Headcount range

251–500 employees

Short description

Geistlich Pharma AG is a 175-year-old Swiss family-owned regenerative biomaterials company that develops and sells bone substitutes, collagen membranes, and soft tissue matrices to dental, orthopedic, and wound care professionals across more than 110 regions globally.

Ownership category

akta.pro rank

Product category

Regenerative Medical Biomaterials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

akta.pro secondary industries

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

Keywords

• Regenerative biomaterials
• Bone substitutes
• Collagen membranes
• Dental regeneration
• Cartilage repair

Headquarters

HQ city

New Jersey

HQ country

Trinidad & Tobago

HQ region

Latin America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device and Biomaterial Sales: Geistlich generates revenue through the sale of regenerative biomaterials and medical devices to dental professionals, orthopedic surgeons, and wound care clinicians. Products are sold directly through subsidiary companies and via distributor networks. Revenue is primarily one-time product purchase (device/biomaterial consumables), with some recurring educational services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Geistlich manufactures and sells regenerative biomaterials — bone substitutes (Geistlich Bio-Oss), collagen membranes (Bio-Gide, Chondro-Gide), soft tissue matrices (Mucograft, Fibro-Gide), wound care collagen scaffolds (Derma-Gide, DermaForm), and titanium scaffolds (Yxoss CBR) — used by dental surgeons, orthopedic surgeons, and wound care clinicians for bone, cartilage, and soft tissue regeneration. The company also markets infection control products (TauroSept) and offers surgical instruments. Its biomaterials are supported by over 2,800 scientific publications and are sold across more than 110 regions through 12 subsidiaries and a distributor network.

Product overview

Geistlich is a Swiss family-owned company and global leader in regenerative medicine, offering a comprehensive portfolio of biomaterial products across dental, orthopedic, and wound care applications. The dental portfolio centers on Geistlich Bio-Oss (natural bone substitute) and Geistlich Bio-Gide (collagen membrane), complemented by soft tissue matrices (Mucograft, Mucograft Seal, Fibro-Gide), bone instruments (Micross, SafeScraper), and the Yxoss CBR titanium scaffold. The orthopedic portfolio features Orthoss bone substitutes, Chondro-Gide bilayer collagen membrane for cartilage regeneration, and the AMIC (Autologous Matrix-Induced Chondrogenesis) treatment technique. Advanced wound care includes Geistlich Derma-Gide and the newly FDA-cleared DermaForm collagen scaffold. Geistlich also offers infectiology products (Geistlich TauroSept) and partner products (OrthoPure XT, Lipogems). With over 2800 scientific publications supporting their products, Geistlich's offerings are grounded in evidence-based regenerative medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Geistlich Bio-Oss Natural bone substitute material that closely resembles the microstructure of human bone. Produced through a patented 5-week (890-hour) manufacturing process that preserves the natural bone structure. Used by dental professionals for bone augmentation, ridge preservation, sinus floor elevation and periodontal regeneration.
• Geistlich Bio-Oss Pen Easy-to-use applicator delivery format of Geistlich Bio-Oss bone substitute for guided bone regeneration procedures in dental surgery.
• Geistlich Bio-Oss Collagen Bone substitute combining 90% Geistlich Bio-Oss granules with 10% porcine collagen to improve handling and integration in guided bone regeneration procedures.
• Geistlich Combi-Kit Combined bone substitute and collagen membrane kit packaged together for guided bone regeneration procedures in dental surgery.
• Geistlich Bio-Gide (and variants: Compressed, Perio, Shape, Forte) Bilayer collagen I/III membrane that is the market-leading dental collagen membrane. The smooth surface prevents cell diffusion while the porous side supports tissue integration. Sold in multiple variants (Compressed, Perio, Shape, Forte) tailored to periodontal applications and specific surgical needs.
• Mucograft and Mucograft Seal 3D collagen matrices designed specifically for soft tissue regeneration in the oral cavity. Mucograft Seal is a ready-to-use circular version intended for socket sealing in ridge preservation procedures, eliminating the need to harvest palatal tissue.
• Fibro-Gide Porous, resorbable, volumetrically stable porcine collagen matrix specifically designed for soft tissue regeneration in the oral cavity. Designed to avoid the need for palatal tissue harvesting.
• Yxoss CBR 3D titanium scaffold for bone regeneration in dental applications, providing structural support for large bone defects. Used by dental surgeons in customized bone augmentation procedures.
• Geistlich Select REGENFAST Hyaluronic acid-based product supporting dental tissue regeneration applications, sold to dental professionals as an adjunct regenerative product.
• Pocket-X Gel Gel formulation for periodontal pocket treatment and soft tissue regeneration in dental applications.
• Allodyn Allograft Allograft bone substitute product for dental bone regeneration procedures, complementing Geistlich's xenograft portfolio.
• Micross Bone Harvester Bone harvesting instrument for collecting autogenous bone particles during dental surgery.
• SafeScraper TWIST and SafeScraper Twist Curve Volumizer Bone scraper instruments for harvesting autogenous bone during dental surgical procedures. The Twist Curve Volumizer is a curved variant for volumetric bone harvesting in specific surgical approaches.
• Geistlich Tack System Membrane fixation system for securing collagen membranes during dental regenerative procedures.
• Orthoss and Orthoss Collagen Bone substitute material for orthopedic applications that closely resembles the inorganic component of human bone tissue. Orthoss Collagen combines the bone substitute with collagen for orthopedic regeneration procedures.
• Chondro-Gide Bilayer collagen I/III membrane developed specifically for cartilage regeneration, serving as the foundation for the AMIC (Autologous Matrix-Induced Chondrogenesis) technique. Used by orthopedic surgeons for cartilage repair in knee, talus, hip and MTP joints.
• AMIC Chondro-Gide Technique Autologous Matrix-Induced Chondrogenesis (AMIC) — a minimally invasive one-step procedure combining bone marrow stimulation (BMS) with Chondro-Gide bilayer collagen membrane. The membrane creates a biological chamber that protects cells and supports cartilage tissue regeneration. Performed via mini-open or arthroscopic technique across knee, talus, hip and MTP joints.
• AMMR (Arthroscopic Matrix-based Meniscus Repair) Arthroscopic Matrix-based Meniscus Repair technique using Chondro-Gide membrane. Damaged meniscus tissue is enveloped in the collagen matrix forming a biological chamber; bone marrow blood aspirate is injected to support healing.
• AMIC Arthroscopic Instruments Specialized arthroscopic instruments for minimally invasive AMIC cartilage repair procedures in orthopedic surgery.
• Geistlich TauroSept Drug and medical device for infection control used by healthcare professionals across various clinical applications. Distributed through pharmacy and medical supply channels.
• Geistlich Derma-Gide Collagen scaffold wound care device for advanced wound care — supports wound healing for chronic and acute wounds. FDA 510(k) cleared via collaboration with StimLabs. Distributed in the U.S. by StimLabs.
• DermaForm Collagen scaffold particulate wound care device designed to protect and manage chronic and acute wounds. Obtained FDA 510(k) clearance in February 2026 through collaboration with StimLabs.

Quantifiable outcome

• A Geistlich product is used every 14 seconds worldwide
• +3 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• StimLabscoreStrategic or Co-development Partner · 12 February 2026StimLabs, a regenerative medicine company based in Roswell, Georgia, collaborated with Geistlich to obtain FDA 510(k) clearance for DermaForm, Geistlich's collagen scaffold particulate wound care device. The partnership leverages Geistlich's biomaterial expertise and StimLabs' regulatory and commercial capabilities. The clearance was announced February 2026.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Organogenesis: Commercial-stage regenerative medicine company focused on advanced wound care (Apligraf, Dermagraft) and surgical biologics. Directly comparable to Geistlich Derma-Gide and the newly FDA-cleared DermaForm in the advanced wound healing space.
• BioHorizons (Henry Schein): Dental implant and regenerative products company (now part of Henry Schein) offering bone grafting materials and membranes that directly substitute for Geistlich's Bio-Oss and Bio-Gide in dental implantology workflows.
• MiMedx Group: Regenerative medicine company specializing in placental tissue allografts for wound care and surgical recovery. Comparable to Geistlich's collagen-based wound care and dental regenerative approach via similar biomaterial-driven healing mechanisms.
• LifeNet Health: Non-profit allograft provider offering demineralized bone matrix and soft tissue grafts for dental, orthopedic, and wound care applications. Directly comparable to Geistlich's bone substitute (Orthoss, Bio-Oss) and soft tissue regeneration (Mucograft, Fibro-Gide) portfolio from an allograft-vs-xenograft angle.
• Integra LifeSciences: Specialty regenerative medicine company with deep portfolios in collagen-based wound care (Integra Dermal Regeneration Template) and orthopedic/ENT biomaterials. Directly comparable to Geistlich Derma-Gide/DermaForm (wound care) and Chondro-Gide/Orthoss (orthopedic regeneration).
• RTI Surgical: Specialty surgical implant company with biologic and metal-based solutions for spine, sports medicine, and dental procedures. Overlaps with Geistlich's orthopedic bone (Orthoss) and dental regenerative portfolio, particularly in sports medicine and cartilage indications.

Broad incumbents

• Medtronic: Diversified global medtech leader with a significant orthopedic biologics franchise (INFUSE bone graft, Grafton DBM) that competes with Geistlich's Orthoss and Bio-Oss in spine and orthopedic surgery, as well as broader regenerative medicine initiatives.
• Zimmer Biomet: Global orthopedic and dental (via ZimVie spinoff) medtech major with significant bone graft substitute and regenerative product lines. Directly comparable to Geistlich's Orthoss and Bio-Oss in orthopedic applications and adjacent to dental regenerative workflows.
• Dentsply Sirona: Large dental equipment and consumables company with regenerative and implant-adjacent product lines. Overlaps with Geistlich in dental bone substitutes and membranes, serving the same clinician base (implantologists, periodontists) with broader portfolio depth.
• Institut Straumann (Straumann Group): Global leader in dental implants and a major supplier of regenerative dental biomaterials (membranes, bone substitutes). Directly comparable to Geistlich's dental regeneration portfolio and frequently paired with Bio-Oss/Bio-Gide in clinical workflows; larger scale and broader implant offering.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/geistlich-sons-limited

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geistlich Sons